Lyka Labs Hits New 52-Week Low at Rs 115.00 Amid Market Struggles

Lyka Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by touching its 52-week low on September 26, 2025, with a new low price recorded. This decline comes amid a broader market trend where the Pharmaceuticals & Drugs sector has seen a decrease of 2.37%.
Today, Lyka Labs outperformed its sector by 1.44%, despite experiencing a consecutive fall over the last three days, resulting in a total decline of 4.73% during this period. The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a challenging performance trajectory.

Over the past year, Lyka Labs has reported a return of -34.63%, significantly underperforming against the Sensex, which has seen a decline of only 6.30%. The company has maintained a high debt-to-equity ratio of 2.75, reflecting its financial leverage. However, it has demonstrated strong management efficiency with a return on capital employed (ROCE) of 17.59% and consistent operating profit growth at an annual rate of 33.02%. Despite the recent price drop, the company has declared positive results for the last five consecutive quarters, showcasing its operational resilience.